Main contents starts here

News and Press Releases

September 7, 2016


Takeda Launches Wearable Digital Technology Pilot Program to Support Patients and Healthcare Providers with Inflammatory Bowel Disease Management



 

Deerfield, IL, September 7, 2016Today, Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), announced the launch of a pilot digital technology program to support patients and physicians with the management of inflammatory bowel disease (IBD). Digital approaches are being used to develop solutions across many sectors of healthcare, with cutting-edge technology elevating and transforming disease diagnostics, measurement, treatment and more. This program, iBData, is designed to intersect healthcare and digital technologies. In partnership with Texas Digestive Disease Consultants (TDDC) and Vanderbilt University Medical Center (VUMC), this pilot program will allow patients with IBD to track their symptoms and lifestyle factors with wearable watch technology. The data will be collected and translated into reports intended to help enhance patient-physician interaction with the goal of improved care.

 

“The wearable aspect of the technology being used for iBData provides an opportunity to investigate how we as physicians monitor, assess and treat our patients,” said Tim Ritter, MD, Medical Director, Luminal Research, TDDC.

 

“We are very excited about this project and its potential for both patients and physicians,” said Dawn M. Beaulieu, MD, assistant professor of medicine, Division of Gastroenterology, Hepatology & Nutrition, VUMC. “Giving patients the power to capture robust, real-time monitoring of their symptoms will help us as physicians to create a personalized treatment plan. Our hope is that this will ultimately result in better disease control and improved IBD care.”

 

The initial rollout of the program will involve approximately 100 patients. iBData aims to improve conversations between patients and physicians in the exam room and between visits, fostering productive and ongoing dialogues, and improve the understanding of individual patients’ conditions. This includes analyzing symptoms, triggers and aggravating factors in an effort to expand the ability to treat individuals and potentially improve outcomes.

 

“At Takeda, part of what fuels our ongoing dedication to advanced research in the field of gastroenterology is our deep understanding of the challenges that dictate unique needs for both patients and physicians managing IBD,” explained Stephanie Brown, vice president, head, Specialty Business Unit, Takeda. “iBData leverages the remarkable capabilities available today when wearable technologies and medicine converge, in an effort to help overcome these challenges. This innovative pilot program will explore new ways to transform care by generating novel insights into the patient experience that physicians can directly utilize.”

 

About Ulcerative Colitis and Crohn’s Disease

Ulcerative colitis (UC) and Crohn’s disease (CD) are marked by inflammation in the lining of the gastrointestinal tract.[1] UC impacts the large intestine only, which includes the colon and the rectum, while CD can impact any part of the digestive tract, and predominantly affects the ileum.[2],[3] There is no known cause for UC and CD, although many researchers believe that the interaction between genes, the body’s immune system, and environmental factors may play a role.[4]

 

About Takeda Pharmaceuticals U.S.A., Inc.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

 

The company has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of R&D focus include central nervous system, cardiovascular and metabolic, gastroenterology, oncology, and vaccines.

 

Takeda Pharmaceuticals U.S.A., Inc. is located in Deerfield, Ill., and is the U.S. marketing and sales organization of Takeda Pharmaceutical Company Limited.

 

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website, www.takeda.us.


 

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.



[1] Knigge KL. Inflammatory bowel disease. Clin Cornerstone. 2002;4(4):49-60.

[2] National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Digestive Diseases Information Clearinghouse. Ulcerative colitis. http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/index.aspx. Published September 2014. Accessed June 15, 2016.

[3] National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Digestive Diseases Information Clearinghouse. Crohn’s disease. http://digestive.niddk.nih.gov/ddiseases/pubs/crohns/index.aspx. Published September 2014. Accessed June 15, 2016.

[4] Crohn’s and Colitis Foundation of America. The Facts about Inflammatory Bowel Disease. http://www.ccfa.org/assets/pdfs/updatedibdfactbook.pdf. Published November 2014. Accessed June 15, 2016.

Contacts:

Contact:     
Linda Calandra     
Takeda Pharmaceuticals U.S.A., Inc.   
TEL: 224-554-4321    
Linda.Calandra@takeda.com  

Page Top